Over the course of this unique Lupus study, fifteen lupus patients will receive eight infusions of autologous (their own) human adipose-derived mesenchymal stem cells (HB-adMSCs) to see how their bodies respond. The first four infusions will be administered every two weeks, followed by monthly infusions for the remaining treatments. Patients will be monitored for up to 12 months to assess improvements in their condition.
“We look forward to collaborating with Lupus Gulf Coast Chapter for this trial. Together, our goal is to raise $1.5 million to ensure the success of this life-changing research, providing lupus patients with the treatments and support they desperately need,” said Donna Chang, founder and CEO of HBFS.
For information about the trial, visit www.hopebio.org. For more information about the Lupus Gulf Coast Chapter, visit www.lupus.org/texasgulfcoast.